南京医药(600713.SH)发布前三季度业绩，归母净利润4.02亿元，同比下降9.03%

Core Viewpoint - Nanjing Pharmaceutical (600713.SH) reported its Q3 2025 results, showing a slight revenue increase but a decline in net profit and non-recurring profit [1] Financial Performance - The company achieved a revenue of 41.135 billion yuan in the first three quarters, representing a year-on-year growth of 0.48% [1] - The net profit attributable to shareholders was 402 million yuan, reflecting a year-on-year decrease of 9.03% [1] - The non-recurring net profit stood at 371 million yuan, down 14.78% year-on-year [1] - Basic earnings per share were reported at 0.31 yuan [1]